Icon

UPTRAVI (nda207947)- (0.2MG,0.4MG,0.6MG,0.8MG,1MG,1.2MG,1.4MG,1.6MG)

SELEXIPAG ACTELION
0.2MG,0.4MG,0.6MG,0.8MG,1MG,1.2MG,1.4MG,1.6MG
Yes No
2036-Dec-01 2020-Dec-21
2022-Dec-21 None
None No
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
3 2 0
Total Other Developers 9
Drugs with Suitability No
0.2MG ** ** - - -
0.4MG ** ** - - -
0.6MG ** ** - - -
0.8MG ** ** - - -
1MG ** ** - - -
1.2MG ** ** - - -
1.4MG ** ** - - -
1.6MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.